Patents by Inventor Jason Kenneth Myers

Jason Kenneth Myers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CGRP receptor antagonists
    Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044163
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Patent number: 8030304
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Grant
    Filed: September 17, 2007
    Date of Patent: October 4, 2011
    Assignee: Eli Lilly and Company
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • 1-(hetero)aryl-3-amino-pyrrolidine derivatives for use as mGluR3 antagonists
    Patent number: 7868014
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Grant
    Filed: October 13, 2005
    Date of Patent: January 11, 2011
    Assignee: Eli Lilly and Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum
  • Thiazole pyrazolopyrimidines CRF1 receptor antagonists
    Publication number: 20100222339
    Abstract: The present invention relates to compounds of Formula (I), pharmaceutical compositions thereof, and use thereof as corticotropin releasing factor 1 (CRF1) receptor antagonists in the treatment of psychiatric and neuroendocrine disorders, neurological diseases, and metabolic syndrome.
    Type: Application
    Filed: September 17, 2007
    Publication date: September 2, 2010
    Inventors: Zhaogen Chen, Chafiq Hamdouchi Hamdouchi, Erik James Hembre, Philip Arthur Hipskind, Jason Kenneth Myers, Takako Takakuwa, James Lee Toth
  • 1-(Hetero)Aryl-3-Amino-Pyrrolidine Derivatives for Use as Mglur3 Antagonists
    Publication number: 20080300266
    Abstract: The present invention relates to compounds of the Formula (I) which are useful for treating conditions associated with mGluR3 receptors, such as depression, schizophrenia and migraine, pharmaceutical compositions thereof, and methods of using the same.
    Type: Application
    Filed: October 13, 2005
    Publication date: December 4, 2008
    Applicant: Eli Lilly And Company
    Inventors: Thomas Charles Britton, Veronique Dehlinger, Colin Peter Dell, Bruce Anthony Dressman, Jason Kenneth Myers, Eric Samuel Nisenbaum
  • Compounds as radioligands for the diagnosis of disease
    Publication number: 20040157878
    Abstract: Radiolabeled ligands useful as probes for determining the relative abundance, receptor occupancy, and/or function of nicotinic acetylcholine receptors. The compounds of Formula I as described herein are labeled with a radioactive isotopic moiety such as 11C, 18F, 76Br, 123I or 125I. Disorders are diagnosed by administering to a mammal a detectably labeled compound and detecting the binding of that compound to the nAChR. The compounds that have been administered are detected using methods including, but not limited to, position emission topography and single-photon emission computed tomography. The present invention is useful in diagnosing a wide variety of diseases and disorders as discussed herein.
    Type: Application
    Filed: December 5, 2003
    Publication date: August 12, 2004
    Inventors: Bruce Nelson Rogers, David W. Piotrowski, Vincent Edward Groppi, Eric Jon Jacobsen, Jason Kenneth Myers, Daniel Patrick Walker, Donn Gregory Wishka, Marc Bradley Skaddan